Polaris Partners

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By leveraging self-supervised learning and integrating human multimodal data, the company aims to enhance the effectiveness and personalization of cancer therapies, thereby improving patient outcomes in oncology.

Livara Health specializes in non-operative, personalized treatment for musculoskeletal conditions, focusing primarily on back and neck pain. The company has developed an orthopedic care management platform that provides a comprehensive, data-driven approach to pain relief. This platform assesses patients' needs and customizes a six-week treatment program, which includes physical therapy coaching and addiction treatment options. Livara aims to help individuals alleviate their musculoskeletal issues through both online and onsite therapy, eliminating the need for surgical interventions.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Sovato Health specializes in remote surgical access, offering a platform that connects skilled surgeons with patients in underserved areas. This platform integrates people, systems, tools, and data to facilitate safe, scalable, and sustainable remote surgical procedures, expanding healthcare resources to new markets and patients.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Best Doctors is a healthcare services company that offers an innovative employee benefit program. This program provides access to global medical expertise for employees facing significant health decisions, ensuring accurate diagnoses and treatments. The company facilitates consultations between patients and top-tier specialists worldwide, enhancing the quality of care while potentially reducing overall healthcare costs.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on developing solutions to mitigate healthcare cyber incidents related to patient data theft, specifically targeting the needs of chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patients’ protected health information (PHI). By adopting a proactive risk management approach, the platform aims to improve patient care, clinician satisfaction, regulatory compliance, and innovation rates, ultimately helping healthcare organizations assess and reduce the risks associated with data breaches.

Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies that mimic T-cells, which are essential components of the immune system, to target cancer cells with high precision. This next-generation approach allows for the assembly of immunotherapies that can reach previously inaccessible cancer cell targets, significantly broadening the scope of antibody therapy. By utilizing T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics aims to enhance the quality of life for cancer patients and unlock new therapeutic potentials across various types of cancer.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at improving cancer treatment outcomes. The company focuses on addressing how tumors manipulate the immune system, creating therapies tailored for specific molecularly defined patient groups. By targeting the critical interactions between tumors and the immune system, Larkspur's approach seeks to enhance patients' immune responses, particularly in colorectal cancer and other malignancies. This strategic focus aims to overcome existing challenges that allow tumors to evade immune detection and attack, thereby advancing the efficacy of cancer therapies.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.

FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Amplifire is a developer of an online learning platform designed to enhance individual performance and knowledge retention across various sectors, including education, healthcare, and corporate markets. The platform utilizes advanced learning algorithms and knowledge analytics to deliver measurable outcomes, helping users learn effectively and perform at their best. By focusing on diagnostic capabilities, Amplifire enables organizations to foster skill development and improve overall performance, ensuring that individuals can contribute effectively in competitive environments.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Foresight Mental Health is a technology-driven provider of psychiatry and therapy services, operating a network of clinics dedicated to mental health and wellness. The company employs a diverse team that includes psychiatrists, therapists, and psychiatric nurse practitioners who deliver care directly to patients. Foresight enhances its treatment offerings through innovative technology developed in collaboration with software and biomedical engineers, aimed at transforming the mental healthcare experience. By utilizing comprehensive patient profiles and a database of scientific research, the company conducts detailed analyses that include genetic profiles and assessments of brain-chemical balance. This holistic approach enables Foresight to offer tailored treatments, ultimately helping patients achieve improved mental health and overall well-being.

Tessa Therapeutics is a biotechnology company specializing in T cell therapy aimed at treating cancer, particularly solid tumors and lymphoma. The company focuses on developing both autologous and allogeneic cell therapies, including virus-specific T-cells and CAR T cells. Tessa Therapeutics aims to harness the body's anti-viral immune response to target and eliminate cancer cells, thereby transforming cancer treatment and enhancing the quality of life for patients. Through its innovative platform, Tessa Therapeutics is committed to advancing therapeutic options for healthcare providers and improving patient outcomes in the fight against cancer.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

76Bio is a biotechnology company based in New York that focuses on developing innovative therapies for patients with life-threatening diseases. Founded in 2020, the company specializes in targeted protein degraders, a class of therapeutics designed to selectively degrade unneeded proteins in the body. By leveraging advanced technology, 76Bio aims to create transformational treatments that address critical medical needs, offering hope for improved outcomes in patients suffering from serious health conditions.

Ankyra is a biotechnology company focused on developing anchored immunotherapy for cancer treatment. The company addresses the limitations of traditional cytokine therapies, which are often restricted due to widespread immune activation and associated toxicity. Ankyra's innovative approach involves the use of its Anchored Immunotherapy Platform to create ANK-101, a stable complex of a modified IL-12 cytokine and aluminum hydroxide, an FDA-approved adjuvant. This combination allows for targeted intratumoral delivery, enhancing the localized retention and activity of IL-12 while reducing systemic side effects. By optimizing the therapeutic potential of anchored immunotherapy, Ankyra aims to improve treatment outcomes for cancer patients, offering a safer and more effective alternative to conventional therapies.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

OM1, Inc. is a digital health company that specializes in developing a platform for healthcare organizations to measure and forecast patient outcomes. The platform is designed to assist hospitals, health systems, and other healthcare providers in meeting various patient reported and clinical outcomes requirements for value-based care programs. By leveraging advanced predictive and prescriptive analytics, OM1 aims to mitigate risks, lower costs, and enhance the understanding of treatment outcomes across the care continuum. The company's technology gathers and synthesizes clinical data to provide AI-driven insights, enabling healthcare organizations to analyze and utilize outcomes data effectively. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

Muna Therapeutics is a biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases, such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying new medicines that preserve cognitive function and enhance resilience against these debilitating conditions, thereby providing individuals affected by neurodegenerative diseases with access to effective treatment options. Through its innovative approach, Muna Therapeutics strives to improve the quality of life for those suffering from these challenging disorders.

Wellthy, Inc. is a concierge service based in New York that assists individuals and families in managing care for chronically ill, aging, or disabled loved ones. Established in 2014, the company connects families with dedicated Care Coordinators who help navigate complex care situations, including aging-related issues such as dementia, diabetes, and cancer, as well as childcare and special needs. Wellthy's platform enables families to efficiently organize appointments, manage tasks, store essential documents, and maintain communication, alleviating the logistical burdens associated with caregiving. The service aims to provide relief to families by coordinating care and addressing related medical, legal, financial, and housing needs.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital treatments for cognitive disorders. The company's core technology involves creating video games that not only engage users but also assess and enhance cognitive abilities. Akili's pipeline focuses on treating and improving symptoms associated with various medical conditions, including ADHD, MDD, ASD, and inflammatory diseases.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Hummingbird Bioscience is a biotechnology company specializing in the development of novel therapeutic antibodies for oncology and immuno-oncology indications. Utilizing systems biology approaches and proprietary computational platforms, they discover and engineer innovative biotherapeutics targeting challenging disease pathways with strong biological validation. Their pipeline includes lead assets HMBD-001 (anti-HER3) and HMBD-002 (anti-VISTA), both in cancer treatment. The company has formed strategic partnerships with Cancer Research UK and Amgen, and received a product development grant from the Cancer Prevention and Research Institute of Texas.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, established in 2019. The company focuses on enhancing healthcare delivery by creating a platform that facilitates collaboration among various stakeholders, including patients, providers, and payers. Cohere Health specializes in intelligent prior authorization, which aligns the needs of physicians and health plans through a customizable service. By utilizing artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process, enabling efficient utilization management. This approach aims to simplify the complexities of the healthcare system, improve communication, and ultimately enhance patient outcomes throughout the healthcare journey.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on developing solutions to mitigate healthcare cyber incidents related to patient data theft, specifically targeting the needs of chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patients’ protected health information (PHI). By adopting a proactive risk management approach, the platform aims to improve patient care, clinician satisfaction, regulatory compliance, and innovation rates, ultimately helping healthcare organizations assess and reduce the risks associated with data breaches.

Livara Health specializes in non-operative, personalized treatment for musculoskeletal conditions, focusing primarily on back and neck pain. The company has developed an orthopedic care management platform that provides a comprehensive, data-driven approach to pain relief. This platform assesses patients' needs and customizes a six-week treatment program, which includes physical therapy coaching and addiction treatment options. Livara aims to help individuals alleviate their musculoskeletal issues through both online and onsite therapy, eliminating the need for surgical interventions.

FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Covetrus is a company focused on enhancing veterinary care through a combination of production, distribution, and management services. It specializes in supply chain solutions, veterinary practice management software, and prescription management, all aimed at improving health and financial outcomes for veterinary practices. By providing these integral services, Covetrus supports the well-being of animals and the professionals who care for them, contributing to advancements in the field of veterinary medicine.

Sesh Therapy Incorporated is a mental health company that delivers online group support through its mobile application. Founded in 2020 and headquartered in San Francisco, California, Sesh provides a range of sessions led by qualified mental health professionals, making mental healthcare more accessible and affordable compared to traditional therapy appointments. The platform aims to connect individuals seeking support in a collaborative environment, enhancing the overall mental health experience.

FidoCure is dedicated to advancing canine cancer care through the use of AI-driven precision medicine. The company has established the largest proprietary learning database for canine cancer by utilizing data from naturally occurring cases and next-generation sequencing. FidoCure focuses on providing personalized medicine services, which go beyond traditional chemotherapy and radiation. By collecting tissue samples for DNA sequencing, the company generates detailed reports that identify genetic mutations influencing treatment options. This approach enables veterinarians and pet owners to implement targeted therapies that specifically address cancer cells, ultimately improving the quality of life for dogs facing cancer. Furthermore, FidoCure bridges the gap between human and veterinary oncology, fostering comparative oncology and creating innovative drug development opportunities that benefit both pets and humans.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Neogene Therapeutics, Inc. is a biotechnology company based in New York, founded in 2018, that focuses on developing T cell therapies for cancer treatment. The company specializes in creating personalized engineered T cells that target neo-antigens, which are mutated proteins present in cancer cells due to DNA mutations. By leveraging advanced technologies, Neogene isolates T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies routinely collected from patients. This process utilizes high-sensitivity DNA sequencing and genetic screening to identify TCRs that can effectively recognize and attack cancer cells. Neogene's innovative approach aims to enhance the precision and efficacy of cancer therapies, offering improved treatment options for patients facing a broad spectrum of cancers.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

Ankyra is a biotechnology company focused on developing anchored immunotherapy for cancer treatment. The company addresses the limitations of traditional cytokine therapies, which are often restricted due to widespread immune activation and associated toxicity. Ankyra's innovative approach involves the use of its Anchored Immunotherapy Platform to create ANK-101, a stable complex of a modified IL-12 cytokine and aluminum hydroxide, an FDA-approved adjuvant. This combination allows for targeted intratumoral delivery, enhancing the localized retention and activity of IL-12 while reducing systemic side effects. By optimizing the therapeutic potential of anchored immunotherapy, Ankyra aims to improve treatment outcomes for cancer patients, offering a safer and more effective alternative to conventional therapies.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Foresight Mental Health is a technology-driven provider of psychiatry and therapy services, operating a network of clinics dedicated to mental health and wellness. The company employs a diverse team that includes psychiatrists, therapists, and psychiatric nurse practitioners who deliver care directly to patients. Foresight enhances its treatment offerings through innovative technology developed in collaboration with software and biomedical engineers, aimed at transforming the mental healthcare experience. By utilizing comprehensive patient profiles and a database of scientific research, the company conducts detailed analyses that include genetic profiles and assessments of brain-chemical balance. This holistic approach enables Foresight to offer tailored treatments, ultimately helping patients achieve improved mental health and overall well-being.

FOLX Health is a telehealth platform based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. Launched in 2020, the platform creates a medical service marketplace specifically designed for queer and trans individuals. FOLX Health offers access to a network of clinicians who understand the unique needs of this community, focusing on services such as gender-affirming hormone therapy, sexual health, and family creation. The platform also provides virtual consultations, discreet delivery of at-home medication kits, and general medical services, aiming to eliminate the barriers and stigma often encountered in traditional healthcare settings. By prioritizing the health and well-being of LGBTQIA+ individuals, FOLX Health fosters a supportive environment for patients to manage their health needs.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Amagma Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2019. The company focuses on the discovery and development of antibody therapeutics aimed at treating inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma targets overactive extracellular proteases that lead to tissue damage and contribute to widespread inflammatory responses. By addressing these mechanisms, the company aims to provide effective and safe therapeutic options for clinicians dealing with such conditions.

Umbulizer is a manufacturer of low-cost, portable breathing devices aimed at reducing patient fatalities, particularly in resource-limited settings. The company designs simple-to-operate, wirelessly monitored products that provide continuous ventilation, helping medical practitioners save lives in emergency situations. Among their offerings is the UMV-001 device, which has proven essential in critical care scenarios. By addressing the urgent demand for life-saving ventilators, Umbulizer contributes significantly to global health efforts, particularly in areas lacking advanced medical resources.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

OM1, Inc. is a digital health company that specializes in developing a platform for healthcare organizations to measure and forecast patient outcomes. The platform is designed to assist hospitals, health systems, and other healthcare providers in meeting various patient reported and clinical outcomes requirements for value-based care programs. By leveraging advanced predictive and prescriptive analytics, OM1 aims to mitigate risks, lower costs, and enhance the understanding of treatment outcomes across the care continuum. The company's technology gathers and synthesizes clinical data to provide AI-driven insights, enabling healthcare organizations to analyze and utilize outcomes data effectively. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.

Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Africa Healthcare Network (AHN) has pioneered the first dialysis chain in Sub-Saharan Africa, aimed at delivering affordable, high-quality dialysis services for patients suffering from Acute Kidney Injury and End-Stage Renal Disease. In a region where existing facilities are limited and often charge exorbitant fees, AHN addresses the critical shortage of accessible dialysis care. The organization leverages its technical expertise and practical experience to establish well-equipped centers, while also focusing on training healthcare professionals to enhance service delivery. As Chronic Kidney Disease and related health issues rise due to urbanization and lifestyle changes, AHN's model prioritizes operational efficiency and cost-effective sourcing of medical supplies, thereby reducing treatment costs for patients. Operating in Rwanda, Tanzania, and Kenya, AHN is committed to increasing access to life-saving dialysis care, ultimately improving patient outcomes while ensuring financial sustainability.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

KenSci Inc. is a healthcare technology company that has developed a machine learning platform aimed at improving risk management for healthcare providers and payers. Founded in 2015 and headquartered in Seattle, Washington, with additional offices in Hyderabad, India, and Singapore, KenSci's platform enables early intervention by predicting clinical, financial, and operational risks. It integrates healthcare data from various sources, including electronic medical records and claims data, to identify patterns and high-risk markers. The platform features a library of pre-built models and modular solutions that can be incorporated into existing workflows, enhancing hospital operations by reducing costs and improving care coordination. Additionally, KenSci employs Explainable AI models to ensure that its risk predictions are both efficient and accountable. The company also has a strategic partnership with T3k Health, further expanding its impact in the healthcare sector.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Genetic Foresight’s mission is to prevent adverse drug reactions, increase therapeutic success rates, and minimize healthcare costs by enabling clinicians to make informed decisions. Founded in 2016, Genetic Foresight provides a genetic test that sequences targeted segments of patients' genomes as well as a comprehensive prescription decision platform that incorporates drug-genome, drug-drug, drug-disease, personal health, lifestyle, and medical and family histories to predict drug response. This allows the clinician to more safely and effectively prescribe medication based on the patient. The report is updated based on newly generated research, newly created drugs, and newly prescribed drugs, making it a lifetime test.

Wellthy, Inc. is a concierge service based in New York that assists individuals and families in managing care for chronically ill, aging, or disabled loved ones. Established in 2014, the company connects families with dedicated Care Coordinators who help navigate complex care situations, including aging-related issues such as dementia, diabetes, and cancer, as well as childcare and special needs. Wellthy's platform enables families to efficiently organize appointments, manage tasks, store essential documents, and maintain communication, alleviating the logistical burdens associated with caregiving. The service aims to provide relief to families by coordinating care and addressing related medical, legal, financial, and housing needs.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Gauss Surgical, Inc. specializes in real-time blood monitoring solutions that enhance clinical decision-making in the healthcare sector. The company has developed a vision-based platform that provides accurate estimations of blood loss, facilitating timely transfusion decisions and improving patient outcomes. Its flagship product, Triton, is utilized in obstetrics to aid in the early detection of postpartum hemorrhage and offers objective metrics for assessing blood loss. Additionally, Gauss Surgical offers Triton OR, designed for operating rooms to measure blood loss from surgical sponges and suction canisters, and Triton L&D, which focuses on vaginal delivery and postpartum care. Founded in 2011, Gauss Surgical operates from its headquarters in Menlo Park, California.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.